Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α Converting Enzyme (TACE): Novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1′ substituents
- 1 March 2008
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (5), 1577-1582
- https://doi.org/10.1016/j.bmcl.2008.01.075
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimizationBioorganic & Medicinal Chemistry Letters, 2003
- Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identificationBioorganic & Medicinal Chemistry Letters, 2003
- Chapter 16. TNF-α converting enzyme (TACE) as a therapeutic targetAnnual Reports in Medicinal Chemistry, 2003
- Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity RelationshipsJournal of Medicinal Chemistry, 2002
- Tumor necrosis factor-α converting enzymeThe International Journal of Biochemistry & Cell Biology, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisThe New England Journal of Medicine, 2000
- Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-αJournal of Medicinal Chemistry, 1999
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinThe New England Journal of Medicine, 1997